**Supplementary Table 1 Baseline clinicopathological characteristics of all patients according to traditional family history scores**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **Total** |  | **Ontario risk score** |  | **Manchester risk score** |  | **Pedigree risk score** |
|  |  |  | **High****N=25** | **Low****N=237** | **p value** |  | **High****N=17** | **Low****N=245** | **p value** |  | **High****N=21** | **Low****N=241** | **p value** |
| **Age** |  |  |  |  | **0.037** |  |  |  | 0.181 |  |  |  | **0.011** |
| <35 | 23 (8.8%) |  | 5 (20.0%) | 18 (7.6%) |  |  | 3 (17.7%) | 20 (8.2%) |  |  | 5 (23.8%) | 18 (7.5%) |  |
|  ⩾35 | 239 (91.2%) |  | 20 (80.0%) | 219 (92.4%) |  |  | 14 (82.3%) | 225 (91.8%) |  |  | 16 (76.2%) | 223 (92.5%) |  |
| Median (range) | 52 (23-71) |  | 43 (26-70) | 52 (23-71) |  |  | 51 (26-68) | 52 (23-71) |  |  | 48 (26-70) | 52 (23-71) |  |
| **Menopausal status** |  |  |  |  | 0.225 |  |  |  | 0.904 |  |  |  | 0.709 |
|  Premenopausal | 127 (48.5%) |  | 15 (60.0%) | 112 (47.3%) |  |  | 8 (47.1%) | 119 (48.6%) |  |  | 11 (52.4%) | 116 (48.1%) |  |
|  Postmenopausal | 135 (51.5%) |  | 10 (40.0%) | 125 (52.7%) |  |  | 9 (52.9%) | 126 (51.4%) |  |  | 10 (47.6%) | 125 (51.9%) |  |
| **T stage** |  |  |  |  | 0.762 |  |  |  | 0.506 |  |  |  | 0.659 |
|  T2 | 56 (21.4%) |  | 4 (16.0%) | 52 (22.0%) |  |  | 2 (11.8%) | 54 (22.0%) |  |  | 3 (14.3%) | 53 (22.0%) |  |
|  T3 | 123 (46.9%) |  | 12 (48.0%) | 111 (46.8%) |  |  | 10 (58.8%) | 113 (46.1%) |  |  | 10 (47.6%) | 113 (46.9%) |  |
|  T4 | 83 (31.7%) |  | 9 (36.0%) | 74 (31.2%) |  |  | 5 (29.4%) | 78 (31.8%) |  |  | 8 (38.1%) | 75 (31.1%) |  |
| **N stage** |  |  |  |  | 0.630 |  |  |  | 0.440 |  |  |  | 0.694 |
|  N0 | 38 (14.5%) |  | 5 (20.0%) | 33 (13.9%) |  |  | 3 (17.7%) | 35 (14.3%) |  |  | 4 (19.0%) | 34 (14.1%) |  |
|  N1 | 189 (74.1%) |  | 16 (64.0%) | 173 (73.0%) |  |  | 13 (76.5%) | 176 (71.8%) |  |  | 15 (71.4%) | 174 (72.2%) |  |
|  N2 | 10 (3.8%) |  | 1 (4.0%) | 9 (3.8%) |  |  | 1 (5.88%) | 9 (3.7%) |  |  | 1 (4.8%) | 9 (3.7%) |  |
|  N3 | 25 (9.6%) |  | 3 (12.0%) | 22 (9.3%) |  |  | 0 | 25 (10.2%) |  |  | 1 (4.8%) | 24 (10.0%) |  |
| **ER status** |  |  |  |  | 0.268 |  |  |  | 0.682 |  |  |  | 0.305 |
|  ER negative | 89 (34.0%) |  | 6 (24.0%) | 83 (35.0%) |  |  | 5 (29.4%) | 84 (34.3%) |  |  | 5 (23.8%) | 84 (34.9%) |  |
|  ER positive | 173 (66.0%) |  | 19 (76.0%) | 154 (65.0%) |  |  | 12 (70.6%) | 161 (65.7%) |  |  | 16 (76.2%) | 157 (65.1%) |  |
| **PR status** |  |  |  |  | 0.620 |  |  |  | 0.655 |  |  |  | 0.329 |
|  PR negative | 74 (28.2%) |  | 6 (24.0%) | 68 (28.7%) |  |  | 4 (23.5%) | 70 (28.6%) |  |  | 4 (19.0%) | 70 (29.0%) |  |
|  PR positive | 188 (71.8%) |  | 19 (76.0%) | 169 (71.3%) |  |  | 13 (76.5%) | 175 (71.4%) |  |  | 17 (81.0%) | 171 (71.0%) |  |
| **HER2 status** |  |  |  |  | 0.644 |  |  |  | 0.897 |  |  |  | 0.439 |
|  HER2 negative | 158 (60.3%) |  | 14 (56.0%) | 144 (60.7%) |  |  | 10 (58.8%) | 148 (60.4%) |  |  | 11 (52.4%) | 147 (61.0%) |  |
|  HER2 positive | 104 (39.7%) |  | 11 (44.0%) | 93 (39.3%) |  |  | 7 (41.2%) | 97 (39.6%) |  |  | 10 (47.6%) | 94 (39.0%) |  |
| **Ki67 index** |  |  |  |  | 0.674 |  |  |  | 0.544 |  |  |  | 0.786 |
|  <50% | 157 (59.9%) |  | 14 (56.0%) | 143 (60.3%) |  |  | 9 (52.9%) | 148 (60.4%) |  |  | 12 (57.1%) | 145 (60.2%) |  |
|  ⩾50% | 105 (40.1%) |  | 11 (44.0%) | 94 (39.7%) |  |  | 8 (47.1%) | 97 (39.6%) |  |  | 9 (42.9%) | 96 (39.8%) |  |
| **Histologic grade** |  |  |  |  | 0.826 |  |  |  | 0.071 |  |  |  | 0.805 |
|  G2 | 92 (35.1%) |  | 10 (40.0%) | 82 (34.6%) |  |  | 8 (47.1%) | 84 (34.3%) |  |  | 8 (38.1%) | 84 (34.8%) |  |
|  G3 | 181 (52.8%) |  | 48 (12.0%) | 129 (54.4%) |  |  | 5 (29.4%) | 136 (55.5%) |  |  | 10 (47.6%) | 131 (54.4%) |  |
|  Unevaluable | 29 (11.1%) |  | 3 (12.0%) | 26 (11.0%) |  |  | 4 (23.5%) | 25 (10.2%) |  |  | 3 (14.3%) | 26 (10.8%) |  |
| **Molecular subtype** |  |  |  |  | 0.683 |  |  |  | 0.546 |  |  |  | 0.611 |
|  Luminal A-like | 21 (8.0%) |  | 1 (4.0%) | 20 (8.4%) |  |  | 0 | 21 (8.57%) |  |  | 1 (4.8%) | 20 (8.3%) |  |
|  Luminal B-like | 183 (69.9%) |  | 20 (80.0%) | 163 (68.8%) |  |  | 14 (82.4%) | 169 (69.0%) |  |  | 17 (81.0%) | 166 (68.9%) |  |
|  HER2-enriched | 25 (9.5%) |  | 2 (8.0%) | 23 (9.7%) |  |  | 1 (5.88%) | 24 (9.8%) |  |  | 2 (9.5%) | 23 (9.5%) |  |
|  Basal-like | 33 (12.6%) |  | 2 (8.0%) | 31 (13.1%) |  |  | 2 (11.8%) | 31 (12.7%) |  |  | 1 (4.8%) | 32 (13.3%) |  |
| **BMI** |  |  |  |  | 0.377 |  |  |  | **0.009** |  |  |  | 0.146 |
|  <25 | 191 (71.3%) |  | 20 (64.5%) | 171 (72.1%) |  |  | 11 (47.8%) | 180 (73.5%) |  |  | 16 (59.3%) | 175 (72.6%) |  |
|  ⩾25 | 71 (28.7%) |  | 11 (35.5%) | 66 (27.9%) |  |  | 12 (52.2%) | 65 (26.5%) |  |  | 11 (40.7%) | 66 (27.4%) |  |

**Abbreviations**: T, tumor; N, nodal; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 2** **Multivariate analysis for** **predicting pCR using Ontario risk score**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Comparison for OR** | **Multivariate analysis (n=262)** |
|  |  | **OR** | **95% CI** | **p value** |
| **Ontario risk score** | High vs low | 0.767 | 0.272 | 2.161 | 0.616 |
| **Age** | ⩾35 vs <35 years | 0.375 | 0.140 | 1.003 | 0.051 |
| **T stage** | T4 vs T3 vs T2 | 0.639 | 0.423 | 0.965 | **0.033** |
| **Nodal status** | Positive vs negative | 1.061 | 0.456 | 2.468 | 0.891 |
| **HorR status** | Positive vs negative | 0.360 | 0.186 | 0.697 | **0.002** |
| **HER2 status** | Positive vs negative | 3.595 | 1.964 | 6.581 | **<0.001** |
| **Ki67 index** | ⩾50% vs <50% | 3.076 | 1.695 | 5.580 | **<0.001** |
| **BMI** | ⩾25 vs <25 | 0.535 | 0.263 | 1.089 | 0.084 |

**Abbreviations**: pCR, pathological complete response; OR, odds ratio; CI, confidence interval; T, tumor; HorR, hormone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 3 Multivariate analysis for predicting pCR using Manchester risk score**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Comparison for OR** | **Multivariate analysis (n=262)** |
|  |  | **OR** | **95% CI** | **p value** |
| **Manchester risk score** | High vs low | 1.146 | 0.366 | 3.589 | 0.815 |
| **Age** | ⩾35 vs <35 years | 0.389 | 0.147 | 1.031 | 0.058 |
| **T stage** | T4 vs T3 vs T2 | 0.635 | 0.421 | 0.960 | **0.031** |
| **Nodal status** | Positive vs negative | 1.066 | 0.459 | 2.477 | 0.883 |
| **HorR status** | Positive vs negative | 0.355 | 0.183 | 0.688 | **0.002** |
| **HER2 status** | Positive vs negative | 3.571 | 1.952 | 6.533 | **<0.001** |
| **Ki67 index** | ⩾50% vs <50% | 3.045 | 1.681 | 5.517 | **<0.001** |
| **BMI** | ⩾25 vs <25 | 0.542 | 0.267 | 1.099 | 0.089 |

**Abbreviations**: pCR, pathological complete response; OR, odds ratio; CI, confidence interval; T, tumor; HorR, hormone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 4 Multivariate analysis for predicting pCR using Pedigree risk score**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Comparison for OR** | **Multivariate analysis (n=262)** |
|  |  | **OR** | **95% CI** | **p value** |
| **Pedigree risk score** | High vs low | 0.893 | 0.301 | 2.645 | 0.838 |
| **Age** | ⩾35 vs <35 years | 0.381 | 0.142 | 1.019 | 0.055 |
| **T stage** | T4 vs T3 vs T2 | 0.639 | 0.423 | 0.965 | **0.033** |
| **Nodal status** | Positive vs negative | 1.063 | 0.457 | 2.470 | 0.887 |
| **HorR status** | Positive vs negative | 0.358 | 0.185 | 0.695 | **0.002** |
| **HER2 status** | Positive vs negative | 3.581 | 1.957 | 6.555 | **<0.001** |
| **Ki67 index** | ⩾50% vs <50% | 3.055 | 1.686 | 5.537 | **<0.001** |
| **BMI** | ⩾25 vs <25 | 0.542 | 0.267 | 1.099 | 0.090 |

**Abbreviations**: pCR, pathological complete response; OR, odds ratio; CI, confidence interval; T, tumor; HorR, hormone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 5 Univariate and multivariate analysis for predictive factors of pCR in T2 tumors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Comparison for OR** | **Univariate analysis (n=56)** |  | **Multivariate analysis (n=56)** |
|  |  | **OR** | **95% CI** | **p value** |  | **OR** | **95% CI** | **p value** |
| **NeoFHS** | High vs low | 6.824 | 1.296 | 35.928 | **0.023** |  | 7.139 | 1.083 | 47.062 | **0.041** |
| **Age** | ⩾35 vs <35 years | 0.106 | 0.012 | 0.947 | **0.045** |  | 0.113 | 0.009 | 1.378 | 0.088 |
| **Nodal status** | Positive vs negative | 1.655 | 0.141 | 19.386 | 0.688 |  | 0.862 | 0.052 | 14.394 | 0.918 |
| **HorR status** | Positive vs negative | 0.522 | 0.168 | 1.623 | 0.261 |  | 0.626 | 0.154 | 2.543 | 0.512 |
| **HER2 status** | Positive vs negative | 1.244 | 0.427 | 3.629 | 0.689 |  | 1.751 | 0.453 | 6.763 | 0.416 |
| **Ki67 index** | ⩾50% vs <50% | 3.864 | 1.265 | 11.805 | **0.018** |  | 3.380 | 0.864 | 13.223 | 0.080 |
| **BMI** | ⩾25 vs <25 | 1.688 | 0.401 | 7.096 | 0.475 |  | 1.616 | 0.291 | 8.982 | 0.584 |

**Abbreviations**: pCR, pathological complete response; OR, odds ratio; CI, confidence interval; NeoFHS, Neo-Family History Score; HorR, hormone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 6 Univariate and multivariate analysis for predictive factors of pCR in grade 3 tumors**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Comparison for OR** | **Univariate analysis (n=141)** |  | **Multivariate analysis (n=141)** |
|  |  | **OR** | **95% CI** | **p value** |  | **OR** | **95% CI** | **p value** |
| **NeoFHS** | High vs low | 2.175 | 1.067 | 4.434 | **0.032** |  | 2.332 | 1.008 | 5.399 | **0.048** |
| **Age** | ⩾35 vs <35 years | 0.792 | 0.242 | 2.586 | 0.699 |  | 0.773 | 0.197 | 3.037 | 0.713 |
| **T stage** | T4 vs T3 vs T2 | 0.562 | 0.350 | 0.901 | **0.017** |  | 0.501 | 0.286 | 0.878 | **0.016** |
| **Nodal status** | Positive vs negative | 1.176 | 0.421 | 3.291 | 0.757 |  | 0.890 | 0.282 | 2.815 | 0.843 |
| **HorR status** | Positive vs negative | 0.600 | 0.291 | 1.235 | 0.165 |  | 0.661 | 0.286 | 1.526 | 0.332 |
| **HER2 status** | Positive vs negative | 2.746 | 1.384 | 5.448 | **0.004** |  | 4.092 | 1.826 | 9.172 | **0.001** |
| **Ki67 index** | ⩾50% vs <50% | 2.500 | 1.263 | 4.950 | **0.009** |  | 2.592 | 1.181 | 5.686 | **0.018** |
| **BMI** | ⩾25 vs <25 | 0.506 | 0.224 | 1.140 | 0.100 |  | 0.533 | 0.214 | 1.330 | 0.178 |

**Abbreviations**: pCR, pathological complete response; OR, odds ratio; CI, confidence interval; NeoFHS, Neo-Family History Score; T, tumor; HorR, hormone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 7 Univariate and multivariate analysis for predictive factors of pCR in node-positive patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Comparison for OR** | **Univariate analysis (n=224)** |  | **Multivariate analysis (n=224)** |
|  |  | **OR** | **95% CI** | **p value** |  | **OR** | **95% CI** | **p value** |
| **NeoFHS** | High vs low | 2.649 | 1.473 | 4.761 | **0.001** |  | 3.088 | 1.498 | 6.367 | **0.002** |
| **Age** | ⩾35 vs <35 years | 0.287 | 0.106 | 0.774 | **0.014** |  | 0.218 | 0.069 | 0.689 | **0.009** |
| **T stage**  | T4 vs T3 vs T2 | 0.573 | 0.391 | 0.839 | **0.004** |  | 0.555 | 0.352 | 0.874 | **0.011** |
| **HorR status** | Positive vs negative | 0.338 | 0.179 | 0.639 | **0.001** |  | 0.436 | 0.210 | 0.903 | **0.025** |
| **HER2 status** | Positive vs negative | 2.597 | 1.469 | 4.592 | **0.001** |  | 3.279 | 1.659 | 6.479 | **0.001** |
| **Ki67 index** | ⩾50% vs <50% | 3.359 | 1.884 | 5.987 | **<0.001** |  | 3.434 | 1.749 | 6.742 | **<0.001** |
| **BMI** | ⩾25 vs <25 | 0.441 | 0.221 | 0.879 | **0.020** |  | 0.497 | 0.228 | 1.079 | 0.077 |

**Abbreviations**: pCR, pathological complete response; OR, odds ratio; CI, confidence interval; NeoFHS, Neo-Family History Score; T, tumor; HorR, hormone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 8 Univariate and multivariate analysis for predictive factors of pCR in HorR-positive patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Comparison for OR** | **Univariate analysis (n=204)** |  | **Multivariate analysis (n=204)** |
|  |  | **OR** | **95% CI** | **p value** |  | **OR** | **95% CI** | **p value** |
| **NeoFHS** | High vs low | 2.009 | 1.026 | 3.933 | **0.042** |  | 2.645 | 1.164 | 6.010 | **0.020** |
| **Age** | ⩾35 vs <35 years | 0.378 | 0.138 | 1.035 | 0.058 |  | 0.342 | 0.105 | 1.114 | 0.075 |
| **T stage** | T4 vs T3 vs T2 | 0.497 | 0.314 | 0.786 | **0.003** |  | 0.570 | 0.336 | 0.966 | **0.037** |
| **Nodal status** | Positive vs negative | 1.184 | 0.499 | 2.810 | 0.701 |  | 1.004 | 0.373 | 2.701 | 0.994 |
| **HER2 status** | Positive vs negative | 3.359 | 1.768 | 6.381 | **<0.001** |  | 3.657 | 1.755 | 7.618 | **0.001** |
| **Ki67 index** | ⩾50% vs <50% | 3.821 | 2.001 | 7.297 | **<0.001** |  | 4.238 | 2.007 | 8.949 | **<0.001** |
| **BMI** | ⩾25 vs <25 | 0.560 | 0.265 | 1.181 | 0.128 |  | 0.466 | 0.193 | 1.127 | 0.090 |

**Abbreviations**: pCR, pathological complete response; HorR, hormone receptor; OR, odds ratio; CI, confidence interval; NeoFHS, Neo-Family History Score; T, tumor; HER2, human epidermal growth factor receptor 2; BMI, body mass index.

**Supplementary Table 9 Univariate and multivariate analysis for predictive factors of pCR in HER2-negative patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Comparison for OR** | **Univariate analysis (n=158)** |  | **Multivariate analysis (n=158)** |
|  |  | **OR** | **95% CI** | **p value** |  | **OR** | **95% CI** | **p value** |
| **NeoFHS** | High vs low | 2.333 | 1.052 | 5.175 | **0.037** |  | 4.786 | 1.550 | 14.775 | **0.006** |
| **Age** | ⩾35 vs <35 years | 0.152 | 0.054 | 0.429 | **<0.001** |  | 0.153 | 0.044 | 0.531 | **0.003** |
| **T stage** | T4 vs T3 vs T2 | 0.404 | 0.232 | 0.704 | **0.001** |  | 0.466 | 0.228 | 0.955 | **0.037** |
| **Nodal status** | Positive vs negative | 1.320 | 0.459 | 3.795 | 0.606 |  | 1.017 | 0.277 | 3.732 | 0.980 |
| **HorR status** | Positive vs negative | 0.227 | 0.100 | 0.517 | **<0.001** |  | 0.383 | 0.136 | 1.078 | 0.069 |
| **Ki67 index** | ⩾50% vs <50% | 6.533 | 2.875 | 14.846 | **<0.001** |  | 6.197 | 2.352 | 16.328 | **<0.001** |
| **BMI** | ⩾25 vs <25 | 0.315 | 0.114 | 0.869 | **0.026** |  | 0.327 | 0.100 | 1.072 | 0.065 |

**Abbreviations**: pCR, pathological complete response; HER2, human epidermal growth factor receptor 2; OR, odds ratio; CI, confidence interval; NeoFHS, Neo-Family History Score; T, tumor; HorR, hormone receptor; BMI, body mass index.

**Supplementary Table 10 Summary of adverse events according to traditional scoring systems**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Events** | **Ontario risk score** |  | **Manchester risk score** |  | **Pedigree risk score** |
|  | **High****N=25** | **Low****N=237** | **p value** |  | **High****N=17** | **Low****N=245** | **p value** |  | **High****N=21** | **Low****N=241** | **p value** |
| **Adverse events of any grade** |  |  |  |  |  |  |  |  |  |  |  |
|  Leukopenia | 23 (92.0%) | 205 (86.5%) | 0.436 |  | 15 (88.2%) | 213 (86.9%) | 0.878 |  | 20 (95.2%) | 208 (86.3%) | 0.243 |
|  Neutropenia | 22 (88.0%) | 197 (83.1%) | 0.531 |  | 15 (88.2%) | 204 (83.3%) | 0.593 |  | 20 (95.2%) | 199 (82.6%) | 0.133 |
|  Anemia | 17 (68.0%) | 160 (67.5%) | 0.960 |  | 9 (52.9%) | 168 (68.6%) | 0.183 |  | 14 (66.7%) | 163 (67.6%) | 0.928 |
|  Elevated aspartate aminotransferase  | 4 (16.0%) | 42 (17.7%) | 0.830 |  | 2 (11.8%) | 44 (18.0%) | 0.516 |  | 2 (9.5%) | 44 (18.3%) | 0.313 |
|  Elevated total bilirubin | 11 (44.0%) | 101 (42.6%) | 0.894 |  | 10 (58.2%) | 117 (47.8%) | 0.377 |  | 9 (42.9%) | 103 (42.7%) | 0.992 |
|  Elevated alanine aminotransferase | 15 (60.0%) | 112 (47.3%) | 0.225 |  | 6 (35.3%) | 106 (43.3%) | 0.521 |  | 12 (57.1%) | 115 (47.7%) | 0.407 |
|  Alopecia | 21 (84.0%) | 154 (65.0%) | 0.073 |  | 12 (70.6%) | 163 (66.5%) | 0.731 |  | 16 (76.2%) | 159 (66.0%) | 0.340 |
|  Nausea | 21 (84.0%) | 135 (57.0%) | **0.009** |  | 12 (70.6%) | 144 (58.8%) | 0.337 |  | 17 (80.9%) | 139 (57.7%) | **0.037** |
|  Peripheral neuropathy | 19 (76.0%) | 137 (57.8%) | 0.078 |  | 11 (64.7%) | 145 (59.2%) | 0.654 |  | 15 (71.4%) | 141 (58.5%) | 0.247 |
|  Diarrhea | 17 (68.0%) | 100 (42.2%) | **0.014** |  | 9 (52.9%) | 108 (44.1%) | 0.477 |  | 14 (66.7%) | 103 (42.7%) | **0.034** |
|  Fatigue | 18 (72.0%) | 103 (43.5%) | **0.006** |  | 10 (58.8%) | 111 (45.3%) | 0.280 |  | 14 (66.7%) | 107 (44.4%) | 0.067 |
|  Vomiting | 11 (44.0%) | 82 (34.6%) | 0.350 |  | 5 (29.4%) | 88 (35.9%) | 0.588 |  | 8 (38.1%) | 85 (35.3%) | 0.795 |
|  Hand-foot syndrome | 10 (40.0%) | 84 (35.4%) | 0.651 |  | 7 (41.2%) | 87 (35.5%) | 0.638 |  | 8 (38.1%) | 86 (35.7%) | 0.825 |
|  Epistaxis | 13 (52.0%) | 83 (35.0%) | 0.094 |  | 5 (29.4%) | 91 (37.1%) | 0.522 |  | 10 (47.6%) | 86 (35.7%) | 0.276 |
|  Rash | 12 (48.0%) | 65 (27.4%) | **0.032** |  | 6 (35.3%) | 71 (29.0%) | 0.580 |  | 10 (47.6%) | 67 (27.8%) | 0.078 |
|  Constipation | 10 (40.0%) | 58 (24.5%) | 0.092 |  | 5 (29.4%) | 63 (25.7%) | 0.737 |  | 7 (33.3%) | 61 (25.3%) | 0.421 |
| **Adverse events ⩾ Grade 3** |  |  |  |  |  |  |  |  |  |  |  |
|  Neutropenia | 10 (40.0%) | 115 (48.5%) | 0.417 |  | 6 (25.3%) | 119 (48.6%) | 0.289 |  | 9 (42.9%) | 116 (48.1%) | 0.642 |
|  Leukopenia | 6 (24.0%) | 67 (28.3%) | 0.651 |  | 4 (23.5%) | 69 (28.2%) | 0.680 |  | 4 (19.1%) | 69 (28.6%) | 0.347 |
|  Anemia | 3 (12.0%) | 8 (3.4%) | **0.041** |  | 1 (5.9%) | 10 (4.1%) | 0.529 |  | 2 (9.5%) | 9 (3.7%) | 0.217 |
|  Thrombocytopenia | 0 | 1 (0.4%) | 1.000 |  | 0 | 1 (0.4%) | 1.000 |  | 0 | 1 (0.4%) | 1.000 |
|  Vomiting | 1 (4.0%) | 9 (3.8%) | 1.000 |  | 0 | 10 (4.1%) | 1.000 |  | 0 | 10 (4.2%) | 1.000 |
|  Fatigue | 0 | 1 (0.4%) | 1.000 |  | 1 (5.9%) | 7 (2.9%) | 0.420 |  | 2 (9.5%) | 6 (2.5%) | 0.128 |
|  Diarrhea | 0 | 5 (2.1%) | 1.000 |  | 1 (5.9%) | 4 (1.6%) | 0.287 |  | 0 | 5 (2.1%) | 1.000 |
|  Peripheral neuropathy | 2 (8.0%) | 6 (2.5%) | 0.171 |  | 0 | 1 (0.4%) | 1.000 |  | 0 | 1 (0.4%) | 1.000 |
|  Nausea | 1 (4.0%) | 1 (0.4%) | 0.182 |  | 0 | 2 (0.8%) | 1.000 |  | 0 | 2 (0.8%) | 1.000 |
| **Serious adverse events** |  |  |  |  |  |  |  |  |  |  |  |
|  Fever | 0 | 1 (0.4%) | 1.000 |  | 0 | 1 (0.4%) | 1.000 |  | 0 | 1 (0.4%) | 1.000 |
|  Diarrhea | 0 | 1 (0.4%) | 1.000 |  | 0 | 1 (0.4%) | 1.000 |  | 0 | 1 (0.4%) | 1.000 |